Itraconazole Capsules 130 mg : Antifungal Power with Itraconazole 130 mg
Fungal infections, whether superficial or systemic, can severely affect quality of life and health. CONARIS SB 130 offers an advanced solution with its powerful antifungal agent Itraconazole 130 mg, formulated to combat a wide range of fungal pathogens effectively. With enhanced absorption technology and a broad spectrum of activity, CONARIS SB 130 ensures reliable treatment outcomes in both acute and chronic fungal conditions.
Introduction to CONARIS SB 130
CONARIS SB 130 is a prescription antifungal medication that contains Itraconazole 130 mg, a triazole derivative known for its potent action against dermatophytes, yeasts, and molds. It is used in the treatment of onychomycosis (fungal nail infections), tinea corporis, tinea pedis, candidiasis, and systemic fungal infections such as histoplasmosis and aspergillosis.
The advanced super bioavailable (SB) formulation of CONARIS SB 130 ensures improved absorption and bioavailability compared to conventional itraconazole capsules, offering faster symptom relief, enhanced tissue penetration, and more consistent plasma levels.
Key Features and Ingredients
Key Features:
Contains Itraconazole 130 mg with super bioavailable technology
Broad-spectrum antifungal activity against skin, nail, and systemic infections
Excellent penetration into keratinous tissues, nails, and mucosa
Improved gastrointestinal tolerance and patient compliance
Effective against resistant fungal strains
Suitable for short-term and long-term use
Active Ingredient:
Itraconazole 130 mg – A potent azole antifungal that inhibits fungal cytochrome P450, preventing the synthesis of ergosterol, an essential component of fungal cell membranes.
Usage and Administration
CONARIS SB 130 should be taken as prescribed by a healthcare provider. It is best absorbed when taken with food, particularly a full meal.
Typical Usage Guidelines:
For dermatophytosis (skin infections): 1 capsule once daily for 7 to 15 days
For onychomycosis (nail infections): Pulse therapy (2 capsules twice daily for 1 week, repeated monthly for 2–3 months) or continuous therapy as directed
For systemic fungal infections: Dosage and duration vary depending on the infection and severity; long-term use may be required
Note: The actual dosage may differ based on the patient's condition, response to therapy, and medical history.
Benefits of CONARIS SB 130
Rapid symptom relief in fungal infections of the skin, nails, and mucous membranes
Enhanced bioavailability ensures better absorption than conventional itraconazole
Deep tissue penetration targets fungal colonies at the root
Fewer relapses due to sustained drug levels in affected tissues
Effective in resistant infections, especially in patients unresponsive to other antifungals
Convenient oral capsule improves patient adherence to therapy
Conclusion
CONARIS SB 130 is a high-performance antifungal therapy formulated with Itraconazole 130 mg, designed to treat a wide range of fungal infections effectively and safely. Its super bioavailable formulation sets it apart by ensuring optimal drug absorption, deeper tissue penetration, and better clinical outcomes. Whether you're treating superficial dermatophyte infections or tackling stubborn systemic mycoses, CONARIS SB 130 provides a reliable, well-tolerated, and results-driven solution.
Choose CONARIS SB 130 – advanced antifungal protection powered by itraconazole.
About The Company
Steris Healthcare Pvt Ltd, widely recognized as Sterispharma, was established in February 2018 by a team of seasoned experts from the pharmaceutical sector. Based in Navi Mumbai, the company is proudly certified by WHO, GMP, and ISO, underscoring its unwavering commitment to quality and patient safety. Sterispharma is driven by a mission to make affordable, premium-quality medicines accessible throughout India, adhering strictly to WHO-recommended standards. Through its user-friendly online pharmacy platforms, customers can effortlessly order medications with home delivery services.
Sterispharma boasts an extensive portfolio of healthcare solutions, ranging from treatments for rare diseases to essential everyday healthcare needs. Their comprehensive product lineup addresses multiple therapeutic areas including Cardiology, Asthma, Respiratory Disorders, Nasal Care, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infective/Antibiotic Therapy, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medications are easily available for online purchase through their official websites — Sterisonline, Sterisindia, and Sterispharma — offering a seamless and reliable healthcare experience.
For further information
Email: info@sterispharma.com / contact@sterispharma.com
Call/WhatsApp: 8209542042 , 8824175417
